3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Breast
1
Conditions
Breast Neoplasms
24
Hereditary Sensory and Autonomic Neuropathies
6
Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
2
Recurrence
2
Ovarian Neoplasms
2
Multiple Endocrine Neoplasia Type 1
2
Head and Neck Neoplasms
2
Advanced Breast Cancer
2
Triple Negative Breast Neoplasms
1
Stomach Neoplasms Esophageal Neoplasms Metastatic Gastric Cancer Mutated PI3KCA Protein Overexpressed HER2 Protein
1
Pre-menopausal Breast Cancer
1
Neoplasm Metastasis
1
Multiple Myeloma
1
Lymphatic Abnormalities
1
Lymphangioma, Cystic
1
Lymphangioma
1
Kidney Neoplasms
1
Hyperglycemia
1
HER2-positive Metastatic Breast Cancer
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Colorectal Neoplasms
1
Carcinoma, Renal Cell
1
Advanced or Metastatic ER+ Breast Cancer
1
Advanced and Selected Solid Tumors
1
Advanced Solid Tumors With an Alteration of the PIK3CA Gene
1
Advanced Solid Tumor
1
Advanced HER2+Breast Cancer
1
Interventions
pertuzumab
1
Trastuzumab
1
Alpelisib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Advanced HER2+Breast Cancer
×
Alpelisib
×
Clear all
NCT04208178
2026-04-02
EPIK-B2
Novartis
Phase 3
Active not recruiting
19 enrolled